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Introduction
Inflammatory bowel disease (IBD) is an idiopathic chronic 
disease with probable genetic heterogeneity affecting nearly 
30 million people worldwide  [1]. Although it is well-
documented that smoking is associated with several 
diseases and with an increased morbidity and mortality of 
smokers [2], several epidemiological observations have 
demonstrated that the risk of developing ulcerative colitis 
(UC) is greater in both ex-smokers and non-smokers [3,4] 
than in smokers. Published evidence also suggests that as 
compared to a healthy population, a higher proportion of 
ABSTRACT
Objective: Previous studies have demonstrated a higher incidence 
of ulcerative colitis in non-smokers. We investigated  the beneficial 
effects of nicotine treatment on colitis-induced anxiety and 
oxidative colonic damage on rats.
Materials and Methods: Wistar Albino (250-300 g) rats (n=40) 
were randomly divided into 5 groups as saline-treated colitis group, 
nicotine pre-treated colitis group, nicotine post-treated colitis group, 
continuously nicotine-treated colitis group and control group. 
Groups received intraperitoneal injections of  saline or nicotine (0.1 
mg/kg/day) for 15 days prior to and for 3 days following the colitis 
induction. Malondialdehyde (MDA) and glutathione (GSH) levels, 
myeloperoxidase (MPO), superoxide dismutase (SOD) and catalase 
(CAT) activities, histological evaluation and DNA fragmentation 
were studied in colonic samples. Anxiety levels were evaluated 
with the  hole-board test. Results were evaluated using ANOVA and 
Mann-Whitney-U tests. 
Results: The saline-treated colitis group had increased MPO 
and MDA levels, DNA fragmentation and histological damage 
scores when compared with the control group. In the nicotine-
treated groups MPO and MDA levels and DNA fragmentation were 
reduced, with lower histologic damage scores.  Reduced SOD, CAT 
and GSH levels were also increased in nicotine-treated groups. 
Conclusion: This study demonstrates antioxidant effects of 
nicotine treatment in the acetic acid-induced colitis model including 
an increased antioxidant capacity, reduced migration of neutrophils 
to the inflamed colon and a reduction of membrane damage.
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ÖZET
Amaç: Epidemiyolojik çalışmalar ülseratif kolitin sigara 
kullanmayanlarda daha sık görüldüğünü bildirmektedir. Bu 
çalışmada kolitle oluşan oksidan hasar ve anksiyete üzerine nikotin 
ön tedavisinin ve/veya kolit sonrası tedavinin olası yararlı etkilerinin 
araştırılması amaçlanmıştır. 
Gereç ve Yöntem: Wistar Albino (250-300 g) sıçanlar (n=40), 
serum fizyolojik (SF) verilen, ön-tedavili, tedavili ve ön-tedavi+ 
tedavili kolit grubu ve kontrol grubu olmak üzere beşe ayrıldı. Kolit 
öncesi 15 gün ve kolit sonrasında 3 gün sıçanlara intraperitoneal SF 
ya da nikotin (0,1 mg/kg/gün) uygulandı. Kolon örneklerinde oksidan 
hasarı belirlemek için malondialdehid (MDA), miyeloperoksidaz 
(MPO) aktivitesi, glutatyon (GSH), süperoksit dismutaz (SOD), 
katalaz ve DNA fragmantasyonu ölçümleri ile histolojik skorlama 
yapıldı. Delikli kutu testi ile anksiyete seviyeleri belirlendi. Sonuçlar 
ANOVA ve Mann Whitney U testi ile analiz edildi. 
Bulgular: Kolitte artan anksiyetenin nikotin ile değişmediği 
gözlendi. SF verilen kolit grubunda kolon MPO ve MDA düzeyleri 
ile DNA fragmantasyonunun ve hasar skorunun kontrol grubuna 
kıyasla arttığı, nikotin verilen tüm kolit gruplarında ise bu hasar 
göstergelerinin anlamlı şekilde düştüğü gözlendi. Histolojik doku 
hasarı skorunun nikotin uygulanan kolit grubunda daha az olduğu 
gözlendi. SOD, katalaz ve GSH düzeylerindeki azalmanın nikotin 
tedavisiyle anlamlı şekilde arttığı gözlendi. 
Sonuç: Çalışmada asetik asitle oluşturulan kolit modelinde, 
nikotin tedavisinin doku antioksidan kapasitesini arttırarak, 
inflamasyon sonucu nötrofil göçünü ve membran hasarını azaltarak 
antioksidan etki oluşturduğu gösterildi.
Anahtar kelimeler: Ulseratif kolit, Anksiyete, Miyeloperoksidaz, 
Superoksit dismutaz, Glutatyon, Katalaz
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IBD patients suffer from anxiety and depression [5], and 
studies of smokers have shown that nicotine can relieve 
stress and reduce anxiety [6]. Based on these observations, 
nicotine, as the primary causative and addictive substance 
in tobacco, has been used as an alternative therapeutic agent 
for treating UC in some clinical trials [7-9].
Major pathogenic characteristics of UC include the 
infiltration of neutrophils into the inflamed colon. When the 
recruitment of polymorphonuclear cells (PMN) and 
macrophages into the colon is increased, a marked increase 
in the production of reactive oxygen metabolites (ROM) 
and pro-inflammatory cytokines will result as a secondary 
amplification of the inflammatory responses [10]. It has 
been shown that in the mucosa of IBD patients chronic and 
relapsing inflammation is characterized by an increased 
expression of pro-inflammatory cytokines such as tumor 
necrosis factor (TNF)-α in immune cells [11, 12]. In 
contrast to this, nicotine was shown to suppress the 
synthesis of eicosanoids [13-15] and pro-inflammatory 
cytokines, interleukin (IL)-1β and TNF-α, and this may 
explain the beneficial effects of smoking and nicotine in 
ulcerative colitis [16]. Moreover, it has also been proved 
that chronic nicotine administration to experimental animals 
results in a significant decrease in the antibody response 
[17] and that chronic in vivo nicotine exposure leads to 
T-cell anergy and may contribute to nicotine/cigarette 
smoke-induced immunosuppression [18].  
Based on these findings, the present study investigated 
the beneficial effects of nicotine treatment on colitis-
induced anxiety and oxidative colonic damage in rats.
Materials and Methods
Animals 
Male Wistar albino rats (250-300 g) supplied by the 
Marmara University (MU) Animal Center (DEHAMER) 
were housed in an air-conditioned room with 12-h light and 
dark cycles, where the temperature (22±2oC) and relative 
humidity (65-70%) were kept constant. All experimental 
protocols were approved by the MU Animal Care and Use 
Committee. 
Induction of colitis and experimental protocol
Before the induction of colitis, animals were fasted for 18 
h. Colitis (n=32) was induced by a modification of the 
method of MacPherson and Pfeiffer [19]. Under light ether 
anesthesia, a polyethylene catheter (PE-60) was inserted 
into the colon with its tip positioned 8 cm from the anus. To 
induce colitis, a solution of 1 ml of 5 % (v/v) acetic acid 
diluted in saline (pH 2.3) was instilled. After a 30 sec 
period of exposure, excess fluid was withdrawn, and the 
colon was then flushed with 1.5 ml of phosphate-buffered 
saline (pH 7.4). The rats in the control group (n=8) were 
subjected to the same procedure with the exception that 
isotonic saline was substituted for acetic acid. The time of 
acetic acid or saline instillation and decapitation was 
identical in all experimental groups. 
The rats were randomly divided into 5 groups.  Animals 
in all groups received intraperitoneal  injections  of  either 
saline or nicotine (nicotine bitartarate, 0.1 mg/kg/day; 
Sigma, St. Louis, MO) for 15 days prior to the colitis 
induction, and injections were continued with saline or 
nicotine for the 3 consecutive days following the colitis 
induction. The saline-treated colitis group (n=8) received 
saline injection before and after the colitis induction. In the 
nicotine pre-treated colitis group (n=8), nicotine injections 
were given for 15 days before the colitis induction and were 
replaced with saline for 3 days following the colitis 
induction. The nicotine post-treated colitis group (n=8) had 
saline injections prior to the colitis induction, but received 
nicotine during the following 3 post-colitis days. Nicotine 
was continued for 18 days in the continuously nicotine-
treated colitis group (n=8). The intracolonic saline instilled 
control group received saline injections for 18 days (n=8).  
On the third day of colonic instillation, all rats were 
decapitated and the last 8 cm of the colon were removed. 
Samples taken from this distal colon region were stored at 
-80oC for subsequent measurement of glutathione (GSH), 
superoxide dismutase (SOD), catalase (CAT) levels and 
myeloperoxidase (MPO) activity. Additional tissue samples 
were obtained for histological evaluation and for the 
determination of DNA fragmentation in the colonic mucosa.
Evaluation of anxiety
Hole-board tests were performed to evaluate the level of 
anxiety on the first day of the experiment before any 
treatments were started. They were repeated on the 15th day 
before colitis induction and on the 3rd day of colitis 
induction. It is well known that an increase in anxiety 
reduces exploratory behavior in rats, which can be tested by 
using the hole-board test [20]. The hole-board apparatus, 
providing a measure of directed exploration in rats [21], 
consisted of a wooden board (40×40 cm) with 16 equally 
spaced holes (each 3 cm in diameter). The hole-board test 
was performed by placing the rat in the center of the 
wooden board, and the test was recorded by a video camera 
for 5 min. Then the number of head-dipping into the holes 
was counted from the videotape [22]. A number of head-
dippings below normal indicated a reduction in the 
exploratory behavior and increased anxiety. 
Assessment of severity of colitis
The rats were decapitated 72 h after the colonic instillation 
of saline or acetic acid and the distal 8 cm of the colons 
were opened down their mesenteric borders and cleansed of 
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luminal contents. For light microscopic investigations, the 
tissues were fixed in 10% formaldehyde and then underwent 
routine histologic preparation before embedding in paraffin. 
For each animal, four randomly taken tissue sections (5µm) 
were cut on a rotary microtome, mounted on slides and 
stained with hematoxylin and eosin. Sections were 
examined under an Olympus BX51 photomicroscope for 
observation of morphological changes. All tissue sections 
were examined by an experienced histologist, who was 
unaware of the treatments. At least five microscopic areas 
were examined to score each specimen. Histological scoring 
was made as 0, none; 1, mild; 2, moderate; 3, severe for 
each of the following criteria: epithelial damage, 
submucosal edema, inflammation and damage in muscularis 
externa. The maximum score calculated was 12. 
GSH and MDA assays
Colonic samples were homogenized in ice-cold 150mM 
KCl for determination of MDA and GSH levels. The MDA 
levels were assayed for products of lipid peroxidation [23]. 
Results were expressed as nmol/g MDA tissue. GSH was 
determined by the spectrephotometric method using 
Ellman’s reagent [24]. Results are expressed as µmol/g 
GSH tissue.
MPO activity
Tissue-associated MPO activity was determined in the 
colonic samples as an indication of accumulation of 
neutrophils. MPO is a natural constituent of primary 
granules of neutrophils, and a direct relationship between 
the MPO activity measured on tissue samples and the 
number of neutrophils has previously been  shown [25]. All 
reagents for MPO assay were obtained from Sigma. The 
tissue samples (0.2–0.3 g) were homogenized in 10 volumes 
of ice-cold potassium phosphate buffer (50mM K2HPO4, 
pH 6.0) containing hexadecyltrimethylammonium bromide 
(HETAB; 0.5%, w/v). The homogenate was centrifuged at 
30,000 g for 10 min at 4oC, and the supernatant was 
discarded. The pellet was then rehomogenized with an 
equivalent volume of 50mM K2HPO4 containing 0.5% 
(w/v) hexadecyltrimethylammonium bromide and 10mM 
ethylenediaminetetraacetic acid (EDTA, Sigma). MPO 
activity was assessed by measuring the H2O2-dependent 
oxidation of o-dianizidine 2HCl. One unit (U) of enzyme 
activity was defined as the amount of MPO present that 
caused a change in absorbance measured at 460 nm for 3 
min. MPO activity was expressed as U/g tissue.
SOD and CAT activities
SOD activity in the colonic samples was measured 
according to a previously described method [26]. Briefly, 
measurements were performed in cuvettes containing 2.8ml 
of 50mM potassium phosphate (pH 7.8) with 0.1mM 
EDTA, 0.1mM of 0.39 mM riboflavin in 10 mM potassium 
phosphate (pH 7.5), 0.1ml of 6 mM of o-dianisidine·2HCl 
in deionized water, and tissue extract (50, 100 ml). Cuvettes 
with all their components were illuminated with 20-W 
Sylvania Grow Lux fluorescent tubes that were placed 5cm 
above and to one side of cuvettes maintaining a temperature 
of 37oC. Absorbances were measured at 460 nm with a 
Shimadzu UV-02 model spectrophotometer. A standard 
curve was prepared routinely with bovine SOD (Sigma–
Aldrich; S-2515-3000 U) as reference. Absorbance readings 
were taken at 0 and 8min of illumination and the net 
absorbances were calculated.
The method for the measurement of CAT activity was 
based on the catalytic activity of the enzyme that catalyzes 
the decomposition reaction of H2O2 to give H2O and O2 
[27]. Briefly, the absorbances of the tissue samples 
containing 0.4 mL homogenate and 0.2 mL H2O2 were read 
at 240 nm and 20oC against a blank containing 0.2 mL 
phosphate buffer and 0.4 mL homogenate for about 1 min.
Colonic DNA fragmentation assay
Mucosal samples (0.10-0.15 mg) from colon were 
homogenized in 10 volumes of a lysis buffer (5 mM Tris 
HCL, 20 mM ethylene diamine tetraacetic acid [EDTA], 
0.5% (v/v) t-octylphenoxypolyethoxyethanol [Triton-X 
100]; pH=8.0). Two separate samples of 1 mL were taken 
from the mucosal samples and centrifuged at 25,000 g for 
30 min to separate the intact chromatin in the pellet from 
the fragmented DNA in the supernatant. The pellet was 
resuspended in 1 mL of Tri-EDTA buffer (pH=8.0), 10 
mM:1 mM.  Both the supernatant and the resuspended 
pellet were assayed for the DNA content by the 
diphenylamine reaction described by Burton [28]. 
Tricarboxylic acid (TCA, 25%) was added to both tubes 
containing the resuspended pellet and supernatant and the 
tubes were kept at 4oC overnight. The samples were then 
centrifuged at 4oC and 25,000 g for 30 min. The 
supernatants were discarded and 5% of freshly prepared 
TCA was added to the pellets in both tubes. The tubes were 
shaken for 20 min at 95oC and a freshly prepared 
diphenylamine (DPA) solution (15 mg DPA dissolved in 1 
mL glacial acetic acid with the addition of 1 mL 
concentrated sulphuric acid) was added in a volume twice 
that of the samples. After the samples were left at 37oC for 
4 h, optical densities were read at 595 nm.
Statistics
Statistical analysis was carried out using GraphPad Prism 
3.0 (GraphPad Software, San Diego, CA). All data were 
expressed as means ± SEM. Groups of data were compared 
with an analysis of variance (ANOVA) followed by Tukey’s 
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multiple comparison tests, and the histological data were 
compared with the non-parametric Mann Whitney U test. 
Values of p<0.05 were regarded as significant. 
Results 
Effect of nicotine treatments on the anxiety levels of rats
Head-dipping numbers that were recorded using the hole-
board test at the beginning of the experiment were not 
different among the experimental groups. Numbers of head-
dippings were significantly reduced in all rats with colitis 
(p<0.05), indicating reduced exploratory behavior and 
increased anxiety, but no differences were evident among 
the treatment regimens (data not shown).
Effect of nicotine treatments on colonic MDA levels, MPO 
activities and DNA fragmentation ratios
In the saline-treated colitis group, colonic MDA level, an 
index of lipid peroxidation, was found to be significantly 
elevated as compared to the control group (p<0.001; Fig. 
1A).  Nicotine, given either as a pre- or post-treatment or as 
a continuous treatment, significantly abolished the elevation 
in MDA levels (p<0.001).  Induction of colitis in saline-
treated rats caused a significant increase in colonic levels of 
MPO activity, a marker of neutrophil infiltration into the 
tissue, compared with that of the control group (p<0.05), 
while only continuous nicotine treatment given to the rats 
with colitis decreased the enzyme activity (p<0.05; Fig. 
1B). In accordance with increased MDA levels and MPO 
activities, DNA fragmentation indicating apoptosis, was 
significantly increased in the saline-treated colitis group as 
compared to the control group (p<0.01; Fig. 1C). However, 
this colitis-induced increase in apoptosis was suppressed by 
nicotine treatments (p<0.05-0.01), while the reduction by 
nicotine pre-treatment did not reach statistical significance.
Effect of nicotine treatments on the extent of colonic 
damage 
Histological analysis by light microscopy revealed that the 
saline-treated colitis group showed moderate damage in the 
epithelium and muscularis externa layer  with mild 
submucosal edema and inflammation, as compared to the 
control group, which demonstrated  a regular colonic 
mucosa and submucosa (Fig. 2). Similarly, in the nicotine 
pre-treated colitis group, moderate epithelial damage and 
submucosal edema along with mild damage in  the 
muscularis  externa  and mild inflammation were observed. 
In the nicotine post-treated and the continuously-treated 
colitis groups, mild epithelial and  damage of the muscularis 
externa with submucosal edema and moderate inflammation 
were evident in the post-treatment group.  Histological 
damage scores in the saline-treated and nicotine-treated 
colitis groups were not statistically different (Fig. 1D).
Figure 1. (A) The malondialdehyde (MDA) levels, (B) 
myeloperoxidase (MPO) activities, (C) percentage of DNA 
fragmentation and (D) histological damage scores of the 
experimental groups.  *p < 0.05, **p<0.01, compared to 
vehicle-treated control group; +p < 0.05, ++p<0.01, 
+++p<0.001, compared to vehicle-treated colitis group. 
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Effect of nicotine treatments on colonic GSH contents 
Induction of colitis in the saline-treated rats caused a 
significant reduction in colonic GSH level when compared 
with that of the control rats (p<0.01).  In contrast to this, 
nicotine treatment in either regimen abolished this reduction 
in GSH content (p<0.01; Fig. 3A). Similarly, SOD activity 
in the saline-treated colitis group demonstrated a significant 
decrease (p<0.05), but the enzyme activity was replenished 
only in the nicotine post-treated colitis group (p<0.05; Fig. 
3B).  When compared with the control group, CAT activity 
Figure 3. (A) Glutathione (GSH) levels, (B) superoxide 
dismutase (SOD) and (C) catalase (CAT) activities of the 
experimental groups.  *p < 0.05, **p<0.01, compared to 
vehicle-treated control group; +p < 0.05, ++p<0.01, 
+++p<0.001, compared to vehicle-treated colitis group. 
Figure 2. (A) Saline-treated colitis group, demonstrating damage in 
the surface epithelium (arrow), Lieberkühn crypts (*) and muscularis 
externa (**). (B) Nicotine pre-treated colitis group with mucosal damage 
(arrow). (C) Nicotine post-treated colitis group, showing mild mucosal 
damage with normal appearance in most of the areas. (D) Continuously 
nicotine-treated colitis group with partial damage in Lieberkühn crypts 
(*) and a normal surface epithelium. Hematoxylen eosin, x100.
Figure 2. (A)
Figure 2. (B)
Figure 2. (C)
Figure 2. (D)
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in the saline-treated colitis group showed a tendency to 
decrease, but the reduction did not reach statistical 
significance (Fig. 3C). However, treatment with nicotine 
with different regimens elevated the CAT activity 
significantly (p<0.05-0.001). 
Discussion
The results of the present study reveal that nicotine 
treatment ameliorates colitis-induced oxidative damage as 
assessed by depressed colonic MDA level, MPO activity 
and mucosal apoptosis concomitant with increased tissue 
GSH content, SOD and CAT activities. Application of a 
15-day pretreatment was equally effective as the 3-day 
post-treatment or the continuous nicotine treatment on most 
of the parameters. However, the effect of nicotine on 
neutrophil infiltration was only evident when nicotine was 
given both before and after the colitis induction.  However, 
colitis-induced anxiety demonstrated by reduced head-
dipping at hole-board test was not altered by nicotine 
treatment. The amount of nicotine injected into the rats in 
the current study (0.1 mg/kg/day) was chosen to correlate 
with the daily intake of nicotine during smoking in humans, 
which was shown to vary widely among subjects (10.5 to 
78.6 mg, i.e. 0.15 to 1.1 mg/kg/day for a 70-kg man) [29].  
Ulcerative colitis is a chronic idiopathic IBD with 
diffuse, recurrent inflammation of the colon and the rectum, 
which is characterized by cycles of acute inflammation, 
ulceration, and bleeding of the colonic mucosa [30]. 
Epidemiological studies have shown that there was a 
distinct lack of current smokers in a cohort of UC patients 
when matched with control subjects [3, 31], while UC 
patients with a smoking history usually acquire their disease 
within 1 or 2 years after they have quit smoking [32-34]. 
Based on this observation, numerous studies have been 
conducted on the relationship between smoking and UC, 
and these have further demonstrated that smoking not only 
protects against the development of UC, but also ameliorates 
the clinical course of the disease [35-41]. Although the 
specific mechanisms underlying the therapeutic effect of 
nicotine are not clear yet, several mechanisms were 
suggested to mediate the beneficial actions of nicotine. In 
support of the anti-inflammatory potential of nicotine, it 
was observed that nicotine inhibited the release of the pro-
inflammatory cytokine TNF-α from immune cells and 
altered the capacity of the cells to respond to TNF-α [42, 
43]. Nicotine was shown to have potent effects on gut 
barrier permeability through an increased expression of 
tight junction proteins [44]. An immunomodulatory effect 
of nicotine is mediated via the α7 subunit of the nicotinic 
ACh receptor (α7 nAChR) on various cells of the immune 
system including T-cells and B-cells, dendritic cells, and 
macrophages [45]. Accordingly, Kolgazi et al [46] have 
recently shown that modulation of the cholinergic system 
by nicotine or ACh esterase inhibition acetic acid-induced 
colonic inflammation and reversed the pro-inflammatory 
cytokine response.  The current study supports  the view 
that nicotine, by modulating the oxidant and antioxidant 
status of the colonic tissue, ameliorates colonic damage 
induced by acetic acid. 
The etiology of UC is not clearly understood, but 
inflammatory mediators, such as excessive production of 
ROM and an increased expression of pro-inflammatory 
cytokines by the inflamed mucosa have been proposed to 
contribute significantly to the development of tissue injury 
[47]. In patients with active episodes of ulcerative colitis, it 
is shown that superoxide and hydrogen peroxide, generated 
by activated leukocytes, are involved in the amplification of 
the inflammatory response and subsequent mucosal 
damage. If the production rate of toxic oxidants exceeds the 
capacity of the endogenous antioxidant enzymes (e.g. 
superoxide dismutase, catalase and glutathione peroxidase) 
exacerbation of the inflammation is inevitable.  Thus, 
enhanced oxidative stress and impaired antioxidant defense 
systems due to the deleterious effect of ROM contribute to 
the pathogenesis of colitis. Despite the detrimental effects 
of nicotine as a result of cigarette consumption, nicotine 
was shown to exert protective action via its direct 
antioxidant effect or by stimulating the antioxidant systems. 
Accordingly, in the current study colitis induction resulted 
in reduced levels of SOD and GSH, while nicotine treatment 
not only replenished these antioxidant stores but also 
increased catalase levels, verifying the supportive role of 
nicotine on the cellular antioxidant capacity.  
There are several possible sources of ROM production 
by the inflamed colon, including the colonic epithelium, the 
microvascular endothelium and/or the inflammatory cells. 
During acute attacks of UC, massive infiltration of 
neutrophils and mononuclear cells into the lamina propria 
and submucosa occurs [48]. Nicotine was discovered to 
enhance neutrophil sequestration, possibly by scavenging 
other oxidants in tobacco smoke [49]. It was previously 
shown that nicotine treatment depresses colonic neutrophil 
recruitment in acetic acid-induced colitis [47]. Exposure to 
tobacco smoke as well as different regimens of nicotine 
administration have attenuated activated colonic MPO 
activity in different models of colitis [50,51]. In accordance 
with these, the present findings also demonstrate that 
nicotine treatment suppresses colonic MPO activity, 
suggesting that the actions of nicotine involve the inhibition 
of the major source of oxidants, neutrophils. 
There is a long history of observations suggesting that 
psychological stress and anxiety contribute to the course of 
IBD [52, 53], whereas chronic stress increases the severity 
of intestinal inflammation [54]. In parallel with previous 
studies demonstrating that psychological stress might 
amplify intestinal inflammation [55], the present data 
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demonstrate that colitis increased the anxiety of the animals 
when placed on the hole-board. However, the degree of 
anxiety was not changed in nicotine-treated rats despite the 
significant attenuation of colonic inflammation.  Studies on 
smokers have shown that nicotine can reduce anxiety and 
relieve stress [56], which may be responsible for smoking 
more cigarettes when under stress. Based on anxiety 
experiments in rodents, it was reported that nicotine can act 
as an anxiolytic and an antidepressant, while adaptation that 
occurs by its chronic use may result in increased anxiety 
and depression following withdrawal [56]. Thus, in the 
current study, the beneficial effect of nicotine given in the 
indicated protocol lacked an anxiolytic action. 
 In conclusion, the results demonstrate that the beneficial 
effects of nicotine in rat acetic acid-induced colitis include 
the inhibition of neutrophils infiltrating the injured colon 
and the maintenance of antioxidant enzymes via the direct 
antioxidant actions of nicotine. 
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